Clinical Trials Browser

Interventional × trastuzumab duocarmazine × Gynecologic × Clear all

NCT04205630 2024-05-30

SYD985 in Patients With HER2-expressing Recurrent, Advanced or Metastatic Endometrial Carcinoma

Phase 2 Completed

64 enrolled 13 charts

Endometrial Neoplasms

NCT04602117 2023-11-18

ISPY-P1.01:Evaluating the Safety of Weekly Paclitaxel With Trastuzumab Duocarmazine (SYD985) in Patients With Metastatic Cancer

Phase 1 Withdrawn

BreastGenitourinaryGynecologic

Urinary Bladder Neoplasms, Breast Neoplasms, Neoplasm Metastasis, Ovarian Neoplasms, Endometrial Neoplasms, Triple Negative Breast Neoplasms